|
| Press Releases |
|
 |
|
| Tuesday, August 26, 2025 |
|
|
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation |
| Essex Bio-Technology Limited ('Essex' and its subsidiary the 'Group', Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor ('rb-bFGF'), today announced its interim results for the six months ended 30 June 2025 ('the period under review'). more info >> |
|
| Wednesday, August 13, 2025 |
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration |
| Essex Bio-Technology Limited ('Essex' or the 'Group', Stock Code: 1061.HK) is pleased to announce that a Biologics License Application ('BLA') for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation ('CDE') of the National Medical Products Administration ('NMPA') in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. ('Henlius', Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration ('wet-AMD') in China. more info >> |
|
|
NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）欣然宣布，集團針對重組抗VEGF眼內注射液EB12-20145P（HLX04-O）的上市註冊申請（「BLA」）最近已被中國國家藥品監督管理局（「NMPA」）藥品審評中心（「CDE」）受理。 more info >> |
|
|
NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请 |
| 亿胜生物科技有限公司（"亿胜生物"或"集团"，股票代码：1061.HK）欣然宣布，集团针对重组抗VEGF眼内注射液EB12-20145P（HLX04-O）的上市注册申请（"BLA"）最近已被中国国家药品监督管理局（"NMPA"）药品审评中心（"CDE"）受理。 more info >> |
|
| Friday, July 25, 2025 |
|
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that(Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC. more info >> |
|
|
億勝生物多劑量地誇磷索鈉滴眼液獲中國國家藥品監督管理局批准上市 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）欣然宣布，集團間接全資附屬公司珠海億勝生物製藥有限公司已收到國家藥品監督管理局批准於中華人民共和國進行多劑量地誇磷索鈉滴眼液（「獲批准産品」）注册及商業化。 more info >> |
|
|
亿胜生物多剂量地夸磷索钠滴眼液获中国国家药品监督管理局批准上市 |
| 亿胜生物科技有限公司（“亿胜生物”或“集团”，股票代码：1061.HK）欣然宣布，集团间接全资附属公司珠海亿胜生物制药有限公司已收到国家药品监督管理局批准于中华人民共和国进行多剂量地夸磷索钠滴眼液（“获批准产品”）注册及商业化。 more info >> |
|
| Monday, March 18, 2024 |
|
|
亿胜生物公布2023年度业绩，收入增长29.5%，利润增长22.1% |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」；股份代码：1061.HK）今日公布截至2023年12月31日止的年度财务业绩。 more info >> |
|
|
億勝生物公布2023年度業績，收入增長29.5%，利潤增長22.1% |
| 億勝生物科技有限公司（「億勝生物」或「集團」；股份代碼：1061.HK）今日公布截至2023年12月31日止的年度財務業績。 more info >> |
|
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1% |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2023. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
康哲藥業（867.HK/8A8.SG）：磷酸蘆可替尼乳膏獲批 為中國批准的首款且唯一白癜風靶向藥
Feb 2, 2026 14:49 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 14:17: JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 13:29 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 13:17 HKT/SGT
|
|
|
富士通、ＳＭＢＣ日興証券様のオンライン取引の不正アクセス対策として、生体認証サービスを導入
Feb 2, 2026 12:30: JST
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 08:00 HKT/SGT
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 18:00: JST
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 17:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00: JST
|
|
|
日清食品（香港）慈善基金连续第四年支持 香港教育大学精英运动员
Jan 31, 2026 07:21 HKT/SGT
|
|
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 22:30: JST
|
|
|
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
